Prevail Therapeutics will soon start its Phase 1/2 clinical trial evaluating the safety, tolerability, and early efficacy of its one-time gene therapy — called PR001 — for Parkinson’s disease associated with mutations in the GBA1 gene. The trial is expected to enroll up to 16 people with confirmed GBA1…
Sun Pharma Advanced Research Company (SPARC) is conducting a Phase 2 clinical study to evaluate the safety and effectiveness of its experimental Abl inhibitor K0706 in people with early Parkinson’s disease. The trial, which is still recruiting, is estimated to enroll approximately 504 participants, age 50 or older,…
A detailed analysis of the structure of alpha-synuclein clumps suggests that Parkinson’s is a systemic disease, whose characteristic protein aggregates can move about inside the brain and migrate beyond the central nervous system, according to a new research. This finding may help in better understanding why Parkinson’s patients experience symptoms other…
Explosions that cause even mild traumatic brain injury can trigger molecular changes that, later in life, lead to neuroinflammation and degeneration, and a greater risk of Parkinson’s disease. But work by researchers at Purdue University also found that analyzing urine levels of a compound called acrolein may help within days of…
New experimental evidence collected from rats shows that alpha-synuclein — the protein that causes Parkinson’s disease — can travel from the intestines to other organs, such as the heart and brain. These findings, reported in the study “Evidence for bidirectional and trans-synaptic parasympathetic and sympathetic…
A Phase 1b clinical trial exploring the oral LRRK2 inhibitor DNL151 has started dosing Parkinson’s patients, the therapy’s developer Denali Therapeutics announced. The 28-day, multicenter, and double-blind study (NCT04056689) is testing two doses of DNL151 against placebo in people with mild to moderate Parkinson’s disease, and with or…
An engineered protein known as AS69 is able to bind to individual units of alpha-synuclein to prevent them from clumping, and — in a fly model of Parkinson’s disease — its use led to preserved motor function, a study reports. The study, “An engineered monomer binding-protein for…
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded AC Immune a new grant to further the development of tracer compounds for Parkinson’s disease (PD). Specifically, this award continues MJFF support for AC Immune’s alpha-synuclein positron-emission tomography (PET) tracer program, aiming for an accurate imaging agent…
Singing a rhythmic tune out loud or, even better, simply listening to it play in your head can help older adults — including those with Parkinson’s disease — to walk more naturally and at a steadier pace, a study reports. The study, “Mental Singing Reduces Gait Variability More Than…
Joined by leaders in Parkinson’s (PD) research and public policy, some 150 patients and advocates from across the nation will gather in Washington, D.C., on Monday for the 2019 Parkinson’s Policy Forum. The annual advocacy event, taking place Sept. 9–10, is presented this…
Get regular updates to your inbox.
